$MDP.TO, a stock that has recently garnered attention, is poised for movement following a trading halt. Investors are speculating on its potential price increase once trading resumes. The stock was previously valued at $10 before a significant event related to Treo, which is nearing approval. Additionally, there is optimism surrounding the drug Terbinafine and its reimbursement prospects in Canada. Some investors have noted that the stock was trading at a 25% free cash flow yield and highlighted insider buying as a positive indicator. Following FDA clearance and expectations for $100 million in revenue, one investor reported a 50% increase in value over a month, though they expressed some regret over selling their shares too early. Overall, the sentiment among investors indicates a belief in the stock's potential value with the right management and market conditions.